Skip to main content
SpringerLink
Log in

Der hämatologisch-onkologische Intensivpatient

Therapie ohne Grenzen

Hematological–oncological intensive care patients

Treatment without borders

  • Leitthema
  • Published:
Medizinische Klinik - Intensivmedizin und Notfallmedizin Aims and scope Submit manuscript

Zusammenfassung

Die Behandlungsmöglichkeiten und Erfolge bei Patienten mit einer Krebserkrankung sind in den letzten Jahren deutlicher, mehr und besser geworden. Vieler dieser Patienten benötigen aber aufgrund von Komorbiditäten, therapieassoziierten Komplikationen oder im Rahmen schwerer Infektionen einen Intensivaufenthalt. Dabei sind die Grenzen zwischen dem intensivmedizinisch Machbaren und Sinnvollen schwer zu ziehen. Über die letzten Jahre ist zunehmend ein Problembewusstsein für diese Krebspatienten auf Intensivstation entstanden und eine Diskussion darüber in Gang gekommen. Dieser Beitrag soll eine Diskussionsgrundlage und auch mögliche Lösungsstrategien anbieten.

Abstract

The number of treatment options and success of treating patients with cancer have both significantly increased in recent years. However, many of these patients require intensive care due to comorbidities, treatment-associated complications, or severe infections. At the same time, the boundaries between what is feasible and sensible are difficult to draw. Over the past few years, awareness of the problems these cancer patients may have in the intensive care unit has increased and discussions have begun. This article intends to offer a discussion basis and also possible solution strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. ABIM Foundation (2019) Choosing Wisely®. http://www.choosingwisely.org/. Zugegriffen: 15. Januar 2019

  2. Azoulay E, Kouatchet A, Jaber S et al (2012) Noninvasive mechanical ventilation in patients having declined tracheal intubation. Intensive Care Med 39:292–301. https://doi.org/10.1007/s00134-012-2746-2

    Article  PubMed  Google Scholar 

  3. Azoulay E, Mokart D, Pène F et al (2013) Outcomes of critically ill patients with hematologic malignancies: Prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 31:2810–2818. https://doi.org/10.1200/JCO.2012.47.2365

    Article  PubMed  Google Scholar 

  4. Azoulay E, Recher C, Alberti C et al (1999) Changing use of intensive care for hematological patients: The example of multiple myeloma. Intensive Care Med 25:1395–1401

    Article  CAS  Google Scholar 

  5. Azoulay E, Soares M, Darmon M et al (2011) Intensive care of the cancer patient: Recent achievements and remaining challenges. Ann Intensive Care 1(1):5. https://doi.org/10.1186/2110-5820-1-5

    Article  PubMed  PubMed Central  Google Scholar 

  6. Centers for Disease Control and Prevention (CDC) (2011) Cancer survivors—United States, 2007. MMWR Morb Mortal Wkly Rep 60:269–272

    Google Scholar 

  7. Crawford SW, Petersen FB (1992) Long-term survival from respiratory failure after marrow transplantation for malignancy. Am Rev Respir Dis 145:510–514. https://doi.org/10.1164/ajrccm/145.3.510

    Article  CAS  PubMed  Google Scholar 

  8. Deutsche Gesellschaft für Innere Medizin (2018) Klug entscheiden. https://www.klug-entscheiden.com/empfehlungen/uebersicht/. Zugegriffen: 15. Januar 2019

  9. Griesenauer RH, Kinch MS (2017) 2016 in review: FDA approvals of new molecular entities. Drug Discov Today 22:1593–1597. https://doi.org/10.1016/j.drudis.2017.06.011

    Article  CAS  PubMed  Google Scholar 

  10. Kiehl MG, Beutel G, Böll B et al (2018) Consensus statement for cancer patients requiring intensive care support. Ann Hematol 97:1271–1282. https://doi.org/10.1007/s00277-018-3312-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zentrum für Krebsregisterdaten, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (2017) Krebs in Deutschland für 2013/2014, 11. Aufl. Robert-Koch-Institut, Berlin

    Google Scholar 

  12. Lanken PN, Terry PB, DeLisser HM et al (2008) An official American thoracic society clinical policy statement: Palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 177:912–927. https://doi.org/10.1164/rccm.200605-587ST

    Article  PubMed  Google Scholar 

  13. Legrand M, Max A, Peigne V et al (2012) Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 40:43–49. https://doi.org/10.1097/CCM.0b013e31822b50c2

    Article  PubMed  Google Scholar 

  14. Massion PB, Dive AM, Doyen C et al (2002) Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med 30:2260–2270. https://doi.org/10.1097/01.CCM.0000030456.11264.EF

    Article  PubMed  Google Scholar 

  15. Miller KD, Siegel RL, Lin CC et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289. https://doi.org/10.3322/caac.21349

    Article  PubMed  Google Scholar 

  16. Neitzke G, Boll B, Burchardi H et al (2017) Documentation of decisions to withhold or withdraw life-sustaining therapies: Recommendation of the ethics section of the German Interdisciplinary Association of Critical Care and Emergency Medicine (DIVI) in collaboration with the ethics section of the German Society for Medical Intensive Care and Emergency Medicine (DGIIN). Med Klin Intensivmed Notfmed 112:527–530. https://doi.org/10.1007/s00063-017-0321-x

    Article  CAS  PubMed  Google Scholar 

  17. Oeyen SG, Benoit DD, Annemans L et al (2013) Long-term outcomes and quality of life in critically ill patients with hematological or solid malignancies: a single center study. Intensive Care Med 39:889–898. https://doi.org/10.1007/s00134-012-2791-x

    Article  CAS  PubMed  Google Scholar 

  18. Pène F, Percheron S, Lemiale V et al (2008) Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med 36:690–696. https://doi.org/10.1097/CCM.0B013E318165314B

    Article  PubMed  Google Scholar 

  19. Puxty K, McLoone P, Quasim T et al (2014) Survival in solid cancer patients following intensive care unit admission. Intensive Care Med 40:1409–1428. https://doi.org/10.1007/s00134-014-3471-9

    Article  PubMed  Google Scholar 

  20. Schellongowski P (2013) Cancer patients in the intensive care unit. Med Klin Intensivmed Notfmed 108:203–208. https://doi.org/10.1007/s00063-012-0177-z

    Article  CAS  PubMed  Google Scholar 

  21. Schellongowski P, Staudinger T, Kundi M et al (2011) Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: A single center experience. Haematologica 96:231–237. https://doi.org/10.3324/haematol.2010.031583

    Article  PubMed  Google Scholar 

  22. Schuster DP (1992) Everything that should be done—not everything that can be done. Am Rev Respir Dis 145:508–509. https://doi.org/10.1164/ajrccm/145.3.508

    Article  CAS  PubMed  Google Scholar 

  23. SEER Datenbank USA (2008) Überlebensdaten USA SEER Register. NCI

  24. Siegel RL, Jemal A, Wender RC et al (2018) An assessment of progress in cancer control: An assessment of progress in cancer control. CA Cancer J Clin 68:329–339. https://doi.org/10.3322/caac.21460

    Article  PubMed  Google Scholar 

  25. Staudinger T, Stoiser B, Müllner M et al (2000) Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med 28:1322–1328. https://doi.org/10.1097/00003246-200005000-00011

    Article  CAS  PubMed  Google Scholar 

  26. Vivot A, Jacot J, Zeitoun J‑D et al (2017) Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol 28:1111–1116. https://doi.org/10.1093/annonc/mdx053

    Article  CAS  PubMed  Google Scholar 

  27. van Vliet M, van den Boogaard M, Donnelly JP et al (2014) Long-term health related quality of life following intensive care during treatment for haematological malignancies. PLoS ONE 9:e87779. https://doi.org/10.1371/journal.pone.0087779

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Vogelzang NJ, Benowitz SI, Adams S et al (2012) Clinical cancer advances 2011: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 30:88–109. https://doi.org/10.1200/JCO.2011.40.1919

    Article  PubMed  Google Scholar 

  29. de Vries VA, Müller MCA, Arbous MS et al (2018) Long-term outcome of patients with a hematologic malignancy and multiple organ failure admitted at the intensive care. Crit Care Med 1. https://doi.org/10.1097/CCM.0000000000003526

    Article  Google Scholar 

  30. Wohlfarth P, Carlström A, Staudinger T et al (2016) Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B‑cell lymphoma. Leuk Lymphoma 57:1831–1838. https://doi.org/10.3109/10428194.2015.1106537

    Article  CAS  PubMed  Google Scholar 

  31. Zimmerman JE, Kramer AA, Knaus WA (2013) Changes in hospital mortality for United States intensive care unit admissions from 1988 to 2012. Crit Care 17:R81. https://doi.org/10.1186/cc12695

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik I für Innere Medizin, Schwerpunkt Internistische Intensivmedizin, Klinikum der Universität zu Köln, Kerpener Str. 62, 50937, Köln, Deutschland

    M. Kochanek, A. Shimabukuro-Vornhagen & B. Böll

  2. Arbeitsgruppe Intensive Care in Hematologic and Oncologic Patients (iCHOP) der DGHO/DGIIN, Köln-Bonn, Deutschland

    M. Kochanek, A. Shimabukuro-Vornhagen & B. Böll

  3. Centrum für Integrierte Onkologie Köln-Bonn, Köln-Bonn, Deutschland

    M. Kochanek

Authors
  1. M. Kochanek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Shimabukuro-Vornhagen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Böll
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Kochanek.

Ethics declarations

Interessenkonflikt

M. Kochanek, A. Shimabukuro-Vornhagen und B. Böll geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

U. Janssens, Eschweiler

W. Druml, Wien

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kochanek, M., Shimabukuro-Vornhagen, A. & Böll, B. Der hämatologisch-onkologische Intensivpatient. Med Klin Intensivmed Notfmed 114, 214–221 (2019). https://doi.org/10.1007/s00063-019-0532-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00063-019-0532-4

Schlüsselwörter

Keywords

Search

Navigation